Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 0.84 · gapped below the open, never looked back. High/low 0.84 at 3:15 pm ET, 0.80 at 9:45 am ET.
Rani Therapeutics Holdings, Inc. has 6 disclosed suppliers and 2 disclosed customers. Each one is named in an SEC filing, either Rani Therapeutics Holdings, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Rani Therapeutics Holdings, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Celltrion will provide, and we will purchase, supply of ustekinumab biosimilar and adalimumab biosimilar at supply prices set forth in the respective Celltrion Agreement.”
FILING10-K0001193125-26-126417cik 0001856725
“Chugai is primarily responsible for preclinical development, and for the manufacturing and supply of the Compound.”
FILING10-K0001193125-26-126417cik 0001856725
“In the case of PG-102 for RT-114, we obtain supply of drug substance from ProGen under the ProGen Collaboration Agreement.”
FILING10-K0001193125-26-126417cik 0001856725
“ICL has agreed to exclusively license certain intellectual property to us for use solely within the Rani Field, but we may not obtain a license on favorable terms.”
FILING10-K0001193125-26-126417cik 0001856725
“Chugai has primary responsibility for preclinical and clinical development, regulatory filings, and commercialization of the Chugai Product, while we are responsible for development of the device and for certain manufacturing and supply activities.”
FILING10-K0001193125-26-126417cik 0001856725
“Chugai paid us an up-front payment of $0.6 million upon execution of the Chugai Research Agreement.”
FILING10-K0001193125-26-126417cik 0001856725
“Chugai is primarily responsible for preclinical development, manufacturing and supply of the Compound, and Rani is primarily responsible for seeking positive regulatory feedback related to the sterility of the microneedle used in the RaniPill, providing regulatory support to Chugai as needed, and performing Chemistry Manufacturing and Controls of the RaniPill.”
FILING10-K0001193125-26-126417cik 0001856725
“In June 2021, we entered into an Amended and Restated Exclusive License Agreement with InCube Labs, LLC ("ICL"), which replaced the 2012 Exclusive License Agreement between ICL and Rani LLC, as amended in 2013, and terminated the 2012 Intellectual Property Agreement between ICL and Rani LLC, as amended in June 2013.”
FILING10-K0001193125-26-126417cik 0001856725
Watchlist prices, news filtered to it, and its next report on your desk.
RANI (Rani Therapeutics Holdings, Inc.) has 6 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.